Pfizer trades at $25.60 with a 6.7% dividend yield, reflecting market caution amid its transition from COVID products to oncology and obesity drugs. Despite strong earnings beats and a low forward P/E, the company faces challenges including declining COVID revenues, rising costs, and a heavy debt load from recent acquisitions. Management remains optimistic about new drug pipelines, but investors are advised to hold and collect dividends while monitoring upcoming trial results and debt management. The consensus target price is $29.19, suggesting moderate upside potential.
Pfizer is undergoing a major transformation, relying on new oncology and obesity assets to offset declining COVID revenues and patent losses. The company offers a 6.7% dividend yield with a payout ratio of about 53% of earnings, but free cash flow co...
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...
Roche Holding AG and Pfizer Inc. are aggressively developing new drugs targeting obesity and type 2 diabetes, aiming to capture growth in the GLP-1 market. Roche's enicepatide shows strong weight loss results in Phase 2 trials with a good safety prof...
In May, the Consumer Price Index (CPI) rose 4.2% year-over-year, matching expectations, with core CPI increasing 0.2%, slightly easing concerns about immediate Federal Reserve rate hikes. Supermicro announced plans to raise up to $7 billion through e...
Ahead of its mega-IPO, SpaceX revealed healthcare ambitions in its SEC filing, highlighting Starlink's role in improving remote healthcare access in underserved areas. The company also envisions manufacturing pharmaceuticals in orbit, leveraging micr...
